About usFlagship projectWhere we workPeopleNews Partner with us

50,000 genomes across Eastern and Central Africa

African genomic data built for drug development.

Cohort recruitment, deep phenotyping, biobanking, biological data generation and interpretation, delivered as one capability.

About us

A genomics institute built where the data is missing

CMB Genomics is an East African public benefit organisation. We recruit and deeply phenotype population cohorts, bank the biospecimens, generate biological data across multiple layers on the same participants, and carry the analysis through to interpreted results.

Cohorts & phenotyping

Recruitment across all 47 Kenyan counties with structured clinical phenotyping at consent.

Biobanking

Consented, barcoded biospecimens under 20-year storage terms.

Biological data generation

Cell biology, molecular and functional data generated on the same participants.

Interpretation

Fine-scale population mapping, immunogenetics and pharmacogenomics, delivered as interpreted results rather than raw files.

Flagship project

50,000 reference genomes across Eastern and Central Africa

A regional reference resource comparable in depth to existing international genome programmes, built under shared governance. It runs in three phases, starting in Kenya and extending through the East Africa Genome Consortium.

Kenya Reference Genome Initiative

1,000 Kenyan adults, all 47 counties, 46 ethnolinguistic groups, at 30× whole genome coverage. Phase 1 of the programme.

Design
Disease-agnostic, census-proportionate recruitment
Multiomics
Layered orthogonal assays on the same participants
Pilot
200+ genomes sequenced across three language families
Status
Phase 1 under way, 2025–2027

East Africa Genome Consortium

National programmes in Uganda, Tanzania, Sudan and Rwanda, each adapted to local regulatory requirements, population structure and institutional partnerships.

Phase 1 · 2025–2027
1,000 Kenyan genomes. Under way.
Phase 2 · 2026–2030
~5,000 genomes across the MOU countries: Uganda, Tanzania, Sudan and Rwanda.
Phase 3 · 2030–2035
50,000 genomes across Eastern and Central Africa.
Where we work

570 million people across the programme footprint

Eleven countries, one active sequencing programme. Population figures from the World Bank, 2025.

Programme countries across Eastern and Central AfricaMap of Africa. Kenya is shown as the active programme and location of the Nairobi headquarters. Uganda, Tanzania, Sudan and Rwanda are in progress with signed memoranda of understanding. Ethiopia, Somalia, South Sudan, DR Congo, Cameroon and Burundi are under exploration. The same information is listed in the table below.TanzaniaDR CongoSomaliaKenyaSudanCameroonBurundiEthiopiaUgandaRwandaSouth SudanTANZANIADR CONGOSOMALIAKENYASUDANCAMEROONETHIOPIAUGANDAS. SUDANBURUNDIRWANDANAIROBI HQ

ActiveIn progress, MOU signedExploration

Programme countries and status
CountryStatusDetail
KenyaActiveUnder way
UgandaIn progressMOU signed
TanzaniaIn progressMOU signed
SudanIn progressMOU signed
RwandaIn progressMOU signed
EthiopiaExplorationIn development
SomaliaExplorationIn development
South SudanExplorationIn development
DR CongoExplorationIn development
CameroonExplorationIn development
BurundiExplorationIn development
Academy

Training scientists who stay

Genomics in the region is constrained by the supply of trained analysts. Academy fellows train inside the programme and stay on it.

Research fellowship
Embedded in active research programmes
Postgraduate partnerships
With regional and international universities
Short courses
Clinical data management, bioinformatics and sequencing
Accredited diploma
In development
People

People

Frank Onyambu, PhD
Chief Science Officer
Google Scholar ↗
Brian Ogoti, PhD
Head of Data and Bioinformatics
Google Scholar ↗
Catherine Waruiru
Head of Laboratory
Alexa Ojijo
Head of Immunogenetics Programme
Samson Koross
Operations
Ivyn Musasia
Regulatory Affairs
Ruskin Gichana, MBA, CFA
Chief Finance Officer
Bridgit Moraa, MBChB
Medical Affairs
News

News

Partner with us

Work with us

We work with pharmaceutical and biotechnology partners, research funders and academic groups on cohort generation, data access and training.